Summary of Significant Accounting Policies - Other (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) customer	Dec. 31, 2023 USD ($)
Product Revenue, net
Number of customers | customer	3
Accounts Receivable, net
Accounts receivable, net	$ 3,840	$ 3,799
Allowance for doubtful accounts	$ 0	0
Payment terms	30 days
ZTALMY
Accounts Receivable, net
Accounts receivable, net	$ 3,300	$ 2,600
Inventory
Cost of product and materials included in research and development expenses prior to FDA approval	$ 2,000
ZTALMY | Revenue Benchmark | Customer Concentration Risk
Product Revenue, net
Number of customers | customer	1
Concentration risk, as a percent	98.00%